Cargando…

Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus Interleukin-2: Induction of autologous tumour-reactive CD4+ Th1 killer lymphocytes

In total, 16 patients with cytologically proven malignant effusion from colorectal cancer were treated by locoregional administration of the streptococcal preparation OK-432 alone or OK-432 plus the T-cell growth factor interleukin (IL)-2, and the action mechanism of the treatment was studied. A pos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, Y, Miyahara, E, Ohshita, A, Kawabuchi, Y, Ohta, K, Shimizu, K, Minami, K, Hihara, J, Sawamura, A, Toge, T
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394446/ https://www.ncbi.nlm.nih.gov/pubmed/14612896 http://dx.doi.org/10.1038/sj.bjc.6601379

Ejemplares similares

Successful pleurodesis with OK-432 in preterm infants with persistent pleural effusion
por: Kim, Jeong Eun, et al.
Publicado: (2012)

OK-432 Treatment of Ranula Intruding into the Cervical Region
por: Ohta, Nobuo, et al.
Publicado: (2022)

Percutaneous Treatment of Renal Cysts with OK-432 Sclerosis
por: Choi, Young Deuk, et al.
Publicado: (2007)

Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells.
por: Colotta, F., et al.
Publicado: (1983)

Picibanil (OK-432) in the treatment of head and neck lymphangiomas in children
por: Rebuffini, Elena, et al.
Publicado: (2012)

The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients
por: Gochi, A, et al.
Publicado: (2001)

OK432 sclerotherapy for refractory chylous leakage after neck dissection
por: Hashimoto, Yuiko, et al.
Publicado: (2023)

Characterization of mouse natural killer cell activating factor (NKAF) induced by OK-432: evidence for interferon- and interleukin 2-independent NK cell activation.
por: Ichimura, O., et al.
Publicado: (1984)

Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity
por: Koya, Terutsugu, et al.
Publicado: (2017)

Chemokines are secreted by monocytes following OK-432 (lyophilized Streptococcus pyogenes) stimulation
por: Olsnes, Carla, et al.
Publicado: (2009)

Risk Factors for Chest Pain and Fever in Patients Undergoing Pleurodesis with OK-432
por: Morimoto, Yoshihito, et al.
Publicado: (2018)

Response to OK-432 sclerotherapy in the treatment of cervical lymphangioma with submucosal extension to the airway()
por: Manzini, Michelle, et al.
Publicado: (2016)

Efficacy of OK-432 sclerotherapy for different types of lymphangiomas: a review and meta-analysis
por: Sun, Jiali, et al.
Publicado: (2023)

Successful treatment of hepatic lymphorrhea by percutaneous transhepatic lymphangiography followed by sclerotherapy using OK-432
por: Kojima, Masayuki, et al.
Publicado: (2019)

CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy
por: Zhang, Juan, et al.
Publicado: (2022)

Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results
por: Kashiwagi, Eiji, et al.
Publicado: (2022)

The Changing Pattern of the Splenic Lymphocyte Subsets in Tumor‐bearing Mice after Oral Treatment with OK‐432
por: Akamatsu, Yoshihiko, et al.
Publicado: (1992)

OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma
por: Wu, Cheng-Jang, et al.
Publicado: (2018)

The usefulness of OK‐432 for the treatment of postoperative chylothorax in a low‐birth‐weight infant with trisomy 18
por: Takahashi, Yoshiaki, et al.
Publicado: (2022)

Treatment of lymphangiomas by means of sclerotherapy with OK-432 (Picibanil®) is safe and effective – A retrospective case series
por: Fasching, G., et al.
Publicado: (2022)

Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation
por: Cao, Yanyan, et al.
Publicado: (2023)

Immunotherapy with Subcutaneous Injection of Immunomodulatory Agent (OK-432) Elicits Durable Response in Locally Advanced or Relapsed Cervical Cancer
por: Alas, Quenny Michelle Dyan A., et al.
Publicado: (2019)

Promising abscopal effect of combination therapy with thermal tumour ablation and intratumoural OK-432 injection in the rat osteosarcoma model
por: Iwai, Tadashi, et al.
Publicado: (2020)

Correction: Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation
por: Cao, Yanyan, et al.
Publicado: (2023)

OK-432 Administration Inhibits Murine Allergic Rhinitis at the Induction Phase, through the Macrophage Activation with TLR2 Signaling Pathway
por: Aoi, Noriaki, et al.
Publicado: (2018)

Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation
por: Kitahara, Masaaki, et al.
Publicado: (2020)

Comparison of the Efficacy and Safety of Single-Session OK-432 and Multiple-Session 99% Ethanol Sclerotherapy for Symptomatic Simple Hepatic Cysts
por: Mo, Zhiqiang, et al.
Publicado: (2022)

Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses
por: Hovden, Arnt-Ove, et al.
Publicado: (2011)

Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer
por: Liu, Zhi-Hua, et al.
Publicado: (2017)

The Bacterial Preparation OK432 Induces IL-12p70 Secretion in Human Dendritic Cells in a TLR3 Dependent Manner
por: Hovden, Arnt-Ove, et al.
Publicado: (2012)

A Case of Sublingual Ranula That Responded Successfully to Localized Injection Treatment with OK-432 after Healing from Drug Induced Hypersensitivity Syndrome
por: Yoshizawa, Kunio, et al.
Publicado: (2016)

Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer
por: Li, Li, et al.
Publicado: (2017)

The Cytocidal Activity of OK‐432‐activated Mononuclear Cells against Human Glioma Cells is Partly Mediated through the Fas Ligand/Fas System
por: Toda, Keisuke, et al.
Publicado: (1996)

I'm OK, you're OK
por: Harris, Thomas A
Publicado: (2004)

The Soluble Factor from Oral Cancer Cell Lines Inhibits Interferon-γ Production by OK-432 via the CD40/CD40 Ligand Pathway
por: Ohe, Go, et al.
Publicado: (2021)

The ok boss
por: James, Muriel
Publicado: (1975)

Is it Still Ok to be Ok? Mental Health Labels as a Campus Technology
por: Armstrong, Neil, et al.
Publicado: (2023)

rf characteristics of a high-power model of the 432 MHz DTL
por: Naito, F, et al.
Publicado: (1995)

Efficacy of Dendritic Cells Matured Early with OK-432 (Picibanil®), Prostaglandin E(2), and Interferon-α as a Vaccine for a Hormone Refractory Prostate Cancer Cell Line
por: Yoo, Changhee, et al.
Publicado: (2010)

High-y OK
Publicado: (1977)

Cannot write session to /tmp/vufind_sessions/sess_34qpf2vr6iuhe7h05r98jknbt5